Ziprasidone: An overview of efficacy and tolerability in the treatment of patients with an acute exacerbation of schizophrenia or schizoaffective disorder

被引：0
|
作者：
Keck, PE
Harrigan, EP
Reeves, KR
机构：
[1] UNIV CINCINNATI,COLL MED,DEPT PSYCHIAT,CINCINNATI,OH 45267
[2] PFIZER INC,PFIZER CENT RES,DEPT CLIN RES,GROTON,CT 06340
来源：
PSYCHOPHARMACOLOGY BULLETIN | 1997年 / 33卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：535 / 535
页数：1
相关论文
共 50 条
  • [41] Ziprasidone in pediatric patients: efficacy and tolerability
    MacMillan, C
    Miller, TP
    Hsin, O
    Johnson, F
    Gonzalez-Heydrich, J
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2004, 14 (04) : 519 - 519
  • [42] Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo-controlled trial
    Daniel, DG
    Zimbroff, DL
    Potkin, SG
    Reeves, KR
    Harrigan, EP
    Lakshminarayanan, M
    NEUROPSYCHOPHARMACOLOGY, 1999, 20 (05) : 491 - 505
  • [43] Ziprasidone 80 mg/day and 160 mg/day in the Acute Exacerbation of Schizophrenia and Schizoaffective Disorder: A 6-Week Placebo-Controlled Trial
    David G Daniel
    Dan L Zimbroff
    Steven G Potkin
    Karen R Reeves
    Edmund P Harrigan
    Mani Lakshminarayanan
    Neuropsychopharmacology, 1999, 20 : 491 - 505
  • [44] Treatment response and gender in patients with schizophrenia and schizoaffective disorder
    Howard, CH
    Fiedosewicz, H
    Patel, C
    Klegon, DA
    Bayog, R
    Berman, I
    SCHIZOPHRENIA RESEARCH, 2001, 49 (1-2) : 232 - 232
  • [45] Subjective tolerability with ziprasidone vs haloperidol in acute schizophrenia
    Awad, AG
    Voruganti, LN
    Mackell, JA
    Siu, CO
    VALUE IN HEALTH, 2003, 6 (03) : 360 - 360
  • [46] CHQ and CGAS in an open-label study of ziprasidone in pediatric patients with bipolar disorder, schizophrenia, or schizoaffective disorder
    DelBello, Melissa
    Stewart, Michelle
    Versavel, Mark
    Keller, David
    Miceli, Jeffrey
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2006, 16 (06) : 662 - 662
  • [47] Effects of oral ziprasidone and risperidone on cognitive functioning in patients with schizophrenia or schizoaffective disorder: Preliminary data
    Mitchell, D
    Hagger, C
    Wise, AL
    Schulz, SC
    SCHIZOPHRENIA RESEARCH, 1997, 24 (1-2) : 116 - 116
  • [48] Psychopharmacological treatment of patients with schizoaffective disorder in comparison to schizophrenia and bipolar disorder
    Assion, H. J.
    Schweppe, A.
    Skiba, M.
    Juckel, G.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2013, 23 : S321 - S322
  • [49] Paliperidone extended-release: a review of efficacy and tolerability in schizophrenia, schizoaffective disorder and bipolar mania
    Canuso, Carla M.
    Battisti, Wendy P.
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (15) : 2557 - 2566
  • [50] Comparison of efficacy and tolerability of quetiapine and haloperidol in acute exacerbation of chronic or subchronic schizophrenia
    Taneli, B
    Alptekin, K
    Bilici, M
    Birsoz, S
    Eker, E
    Cosar, B
    Goka, E
    Goktepe, E
    Guz, H
    Karamustafalioglu, O
    Kultur, S
    Levent, BA
    Onder, E
    Oral, T
    Ozsahin, AÖ
    Veznedaroglu, B
    Yuksel, S
    Yurtseven, N
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2003, 13 : S287 - S287
12345